Amarin Corporation plc (AMRN) Q2 2012 Earnings Call August 8, 2012 4:30 pm ET Executives Stephen D. Schultz – Investor Relations Joseph S. Zakrzewski – Chairman and Chief Executive Officer Frederick W. Ahlholm – Vice President of Finance Joseph T. Kennedy – Senior Vice President, General Counsel and Secretary, Chief Compliance Officer Steven Ketchum – President of Research and Development and Senior Vice President Analysts Dewey Steadman – JPMorgan Chase Tommy B. Nguyen – Jefferies & Co., Inc. Ram Selvaraju – Aegis Capital Corp. PresentationOperator
Greetings and welcome to the Amarin Corp. Second Quarter 2012 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Steve Schultz, Senior Director of Investor Relations for Amarin Corp. Thank you, Mr. Schultz. You may begin. Stephen D. Schultz Welcome, and thank you for joining us today. Please be aware that this conference call will contain will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to, our current expectations regarding regulatory filings, regulatory approvals, potential indications and commercial success of our product candidates and approved product, our current expectations regarding the cardiovascular outcome study and the potential implications of any such study on our regulatory process, plans to protect the commercial potential of our product candidates and approved product by obtaining patents and regulatory exclusivity, maintaining trade secrets and taking advantage of manufacturing barriers to entry, our current expectations regarding a potential strategic collaboration, manufacturing efforts and preparations for commercialization of our product candidates and approved product and our expectations for future publication and presentation of our study data and our future expenses and the adequacy of our financial resources.